Medical Oncology Referral and Systemic Therapy of Patients with Advanced Stage Urothelial Carcinoma

Aim

To understand physician visit patterns among patients with stage IV (including nonmetastatic [M0] and metastatic [M1] disease) urothelial carcinoma (UC) and understand factors associated with a timely referral to a medical oncologist and systemic treatment.

Patients & Methods

Retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data.

Results

First physician encounter was with a urologist (M0: 69%; M1: 53%) or primary care physician ([PCP]; M0: 19%, M1: 25%) for the majority of patients around UC diagnosis. After the index urologist encounter, most patients had a subsequent medical oncologist visit at a median of 52 days (M0: 69.5 days, M1: 33 days). In an adjusted model, older age, index PCP visit, higher comorbidities and M0 disease were negatively associated with a medical oncologist referral. Among those referred to a medical oncologist, older age, Hispanic or non-Hispanic Black race and not being married were negatively associated with subsequent chemotherapy receipt (p < 0.05).

Conclusion

Many patients with advanced UC encounter multiple specialists during their disease course. Older patients or those with a first UC-related encounter with a PCP are less likely to be referred to medical oncology. Once referred to medical oncology, social determinants, including race and marital status, are relevant predictors of receiving chemotherapy.

AuthorsA Abdalla, C Johnson, Y Doleh, R Shenolikar, MF Botteman, A Hussain
JournalJournal of Comparitive Effectiveness Research
Therapeutic AreaOncology
Service AreaModeling & Meta-Analysis
Year2020
LinkClick Here